

**ASX: SKF** 

The Manager Company Announcements Office ASX Limited 20 Bridge Street SYDNEY NSW 2000

Dear Sir/Madam

### Appendix 3B

Skyfii Limited (ASX:SKF) confirms the attached Appendix 3B.

This notification is for the issue of 335,730 Fully Paid Ordinary shares to staff (non-Directors) as part of their agreed remuneration agreements.

1

**Koreen White** 

**Company Secretary** 

Rule 2.7, 3.10.3, 3.10.4, 3.10.

### Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \ Origin: Appendix 5 \ Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 4/03/13$ 

Name of entity

SkyFii Limited

ABN		
20 009 26	64 699	
We (the	entity) give ASX the following	g information.
	• All issues complete the relevant sections (attach	n sheets if there is not enough space).
	Class of *securities issued or to	Fully Paid Ordinary Shares (Shares)
to ma	umber of *securities issued or be issued (if known) or aximum number which may issued	335,730
+se ex pa an da +cc	rincipal terms of the ecurities (e.g. if options, ercise price and expiry date; if artly paid *securities, the nount outstanding and due ates for payment; if onvertible securities, the enversion price and dates for onversion)	Shares rank equally with quoted shares coded SKF
C 1	tor to for defined terms	
Soo on ant		

<sup>+</sup> See chapter 19 for defined terms,

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  the date from which they do  the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Refer 3. above.
5	Issue price or consideration	\$0.133 per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Issued to staff (non Directors) as part of agreed remuneration agreements.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	30 November 2016
6c	Number of *securities issued without security holder approval under rule 7.1	335,730

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval	NA	
	under rule 7.1A		
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	NA	
6f	Number of *securities issued under an exception in rule 7.2	NA	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	NA	
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	NA	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer Schedule	
7	<sup>+</sup> Issue dates	25 July 2018	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.		
		Number	<sup>+</sup> Class
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	273,277,519	Fully paid ordinary shares

<sup>+</sup> See chapter 19 for defined terms.

		NT 1	
		Number	+Class
9		4,655,000	2015 ESP Shares. Various vesting
	+securities not quoted on ASX		dates.
		1,825,000	2016 ESP Shares. Various vesting
	section 2 if applicable)		dates.
	Tr	5,000,000	Unquoted Directors Options,
		),000,000	various Exercise prices
		12 502 000	2016 ESP Shares. Various vesting
		12,703,000	dates.
		800,000	2017 ESP Shares. Various vesting
			dates.
		6,000,000	2017 ESP Shares. Various vesting
			dates.
		2,000,000	2018 ESP Shares. Various
			vesting dates.
10	Dividend policy (in the case of a	N/A	
10	trust, distribution policy) on the	11/11	
	increased capital (interests)		
	mercused cupitur (meercses)	<u> </u>	
<b>.</b> .	0 D		
Part	2 - Pro rata issue		
11	Is security holder approval	N/A	
11	required?	14/11	
	requireu:		
12	Is the issue renounceable or non-	N/A	
	renounceable?		
13	Ratio in which the *securities	N/A	
15	will be offered	11/11	
	will be offered		
	+61 6+ 1:1.1	NT/A	
14	*Class of *securities to which the	N/A	
	offer relates		
15	<sup>+</sup> Record date to determine	N/A	
	entitlements		
		<del>_</del>	
16	Will holdings on different	N/A	
	registers (or subregisters) be	-	
	aggregated for calculating		
	entitlements?	·	
	Characteristics;		
	Dalta Can Joseph and	NT/A	1
17	Policy for deciding entitlements	N/A	
	in relation to fractions		
,0	Names of countries in which the	N/A	
18			
	entity has security holders who		
	will not be sent new offer		
	documents		
	Note: Security holders must be told how their		
	entitlements are to be dealt with. Cross reference: rule 7.7.		
	raic /-/.		

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 4 04/03/2013

19	Closing acceptan		•	of	N/A
	acceptan	 	cracionio		

+ See chapter 19 for defined terms.

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

32	of the	do security holders dispose ir entitlements (except by brough a broker)?	N/A
33	<sup>+</sup> Issue	date	N/A
		Jotation of Securities	
34	Type o	of *securities one)	
(a)	X	*Securities described in Part	1
(b)			nd of the escrowed period, partly paid securities that become fully paid en restriction ends, securities issued on expiry or conversion of convertible
		have ticked box 34(a) securities forming a new	class of securities
Tick to docume		you are providing the informati	ion or
35			securities, the names of the 20 largest holders of the he number and percentage of additional *securities
36			securities, a distribution schedule of the additional amber of holders in the categories
37	_	A copy of any trust deed for	the additional <sup>+</sup> securities

<sup>+</sup> See chapter 19 for defined terms.

Entit	ies that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and +class of all +securities quoted on ASX (including the +securiti es in clause 38)	Number	+Class

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  +securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>†</sup>quotation of the <sup>†</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 25 July 2018

(Company secretary)

Print name: Ms Koreen White

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

Rule 7.1 – Issues exceeding 15% of capital				
Step 1: Calculate "A", the base fig capacity is calculated	ure from which the placement			
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	170,090,551			
Add the following:	40,043,922 (3B dated 21 December 2016, shareholder approved 6 February 2017)			
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	1,587,301 (Directors Fees ratified 3B dated 21 December, shareholder approved 6 February 2017)			
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with</li> </ul>	13,000,000 (Shareholder approved ESP Shares, 3B dated 10 February 2017)			
shareholder approval	26,379,052 (3B dated 10 February 2017, shareholder approved 6 February 2017)			
<ul> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> </ul>	7,793,643 (3B dated 14 February 2017, SPP issue)			
Note:	800,000 (Shareholder approved ESP shares, 3B dated 12 October 2017)			
Include only ordinary securities here – other classes of equity securities cannot be added	1,428,572 (Shareholder approved Directors shares, 3B dated 23 November 2017)			
<ul> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> </ul>	6,000,000 (Shareholder approved ESP shares, 3B dated 11 December 2017)			
<ul> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	1,000,000 (Shareholder approved ESP shares, 3B dated 6 April 2018)			
	1,000,000 (Shareholder approved ESP shares, 3B dated 8 June 2018)			
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	0			
"A"	269,123,041			

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 10 04/03/2013

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	40,368,456
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule
Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:	538,660 shares: Appendix 3B 15052017
Under an exception in rule 7.2	3,800,000 share: Appendix 3B 25072017
Under rule 7.1A	289,855 share: Appendix 3B 25082017
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	25,000,000 share: Appendix 3B 07022018
<ul> <li>Note:         <ul> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> </ul> </li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	488,168 share: Appendix 3B 08022018 335,730 share: Appendix 3B 25072018
"C"	30,452,413
Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1  "A" x 0.15  Note: number must be same as shown in Step 2	B"] to calculate remaining 40,368,456
Subtract "C"	30,452,413
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.15] – "C"	9,916,043
	[Note: this is the remaining placement capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

### Rule 7.1A – Additional placement capacity for eligible entities

## Step 1: Calculate "A", the base figure from which the placement capacity is calculated

"**A**" 269,123,041

Note: number must be same as shown in Step 1 of Part 1

### Step 2: Calculate 10% of "A"

**"D"** 0.10

Note: this value cannot be changed

**Multiply** "A" by 0.10 26,912,304

## Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used

*Insert* number of <sup>+</sup>equity securities issued or agreed to be issued in that 12 month period under rule 7.1A

#### Notes:

- This applies to equity securities not just ordinary securities
- Include here if applicable the securities the subject of the Appendix 3B to which this form is annexed
- Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained
- It may be useful to set out issues of securities on different dates as separate line items

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A			
"A" x 0.10	26,912,304		
Note: number must be same as shown in Step 2			
Subtract "E"	0		
Note: number must be same as shown in Step 3			
<i>Total</i> ["A" x 0.10] – "E"	26,912,304		
	Note: this is the remaining placement capacity under rule 7.1A		

<sup>+</sup> See chapter 19 for defined terms.